Single-Agent Thalidomide for Treatment of Malignant Paraganglioma of the Organ of Zuckerkandl
The standard of care for benign pheochromocytomas and paragangliomas is surgical resection; however, there is no definitive curative or standard therapy for the treatment of malignant pheochromocytomas or paragangliomas. Current therapeutic options include surgical resection, chemotherapy (CVD thera...
Saved in:
Main Authors: | Mackenzie L. Shindorf, Prabir K. Chaudhuri |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Medicine |
Online Access: | http://dx.doi.org/10.1155/2019/7185973 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Rare Coincidence: Nonrecurrent Laryngeal Nerve Pointed by a Zuckerkandl's Tubercle
by: Emin Gurleyik, et al.
Published: (2012-01-01) -
Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01) -
Giant presacral paraganglioma
by: Chunhua Ma, et al.
Published: (2025-02-01) -
Head and Neck Paragangliomas: 16-year Single-center Experience and Mini Review on Diagnosis, Treatment, and Follow-up
by: Gokce AYDEMIR, et al.
Published: (2024-09-01) -
A Novel Green Synthesis of Thalidomide and Analogs
by: Ellis Benjamin, et al.
Published: (2017-01-01)